Showing 3331-3340 of 5773 results for "".
- EyeSouth Partners Affiliates with Retina and Vitreous of Texashttps://modernod.com/news/eyesouth-partners-affiliates-with-retina-and-vitreous-of-texas/2481807/EyeSouth Partners has announced that it has partnered with Retina and Vitreous of Texas (RVT), in Houston. The affiliation represents EyeSouth’s 38th overall and the network’s first retina-only affiliation in the state of Texas. Financial terms of the deal were not disclosed
- Amgen and Horizon Therapeutics Resolve FTC Lawsuit Clearing Path to Acquisitionhttps://modernod.com/news/amgen-and-horizon-therapeutics-resolve-ftc-lawsuitclearing-path-to-acquisition/2481806/Amgen and Horizon Therapeutics announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. The order clears a path forward to closing its planned $27.8-billion takeout 
- OcuCell Secures Funding from The Eye-Bank for Sight Restorationhttps://modernod.com/news/ocucell-secures-funding-from-the-eye-bank-for-sight-restoration/2481804/Ocular cell therapy company OcuCell announced it has received seed funding from The Eye-Bank for Sight Restoration (EBSR). The funding will enable OcuCell to accelerate its mission of transforming the corneal cell therapy landscape through the development of cell therapy solut
- Zeiss to Introduce New Cataract and Corneal Refractive Workflow Enhancements at ESCRS 2023https://modernod.com/news/zeiss-to-introduce-new-cataract-and-corneal-refractive-workflow-enhancements-at-escrs-2023/2481803/Zeiss will showcase new ophthalmic innovations within the cataract and corneal refractive workflows at the European Society of Cataract and Refractive Surgery (ESCRS) annual conference from Sept. 8-12, 2023, in Vienna, Austria. As part of the
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- Sydnexis Appoints Nick Ruth Chief as Commercial Officerhttps://modernod.com/news/sydnexis-appoints-nick-ruth-chief-as-commercial-officer/2481799/Sydnexis has announced the appointment of industry veteran Nick Ruth, MBA, as its Chief Commercial Officer (COO). Mr. Ruth will lead Sydnexis’ commercial strategy and transition from a clinical based organization to both a clinical and commercial based organization. With
- Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposiumhttps://modernod.com/news/abstract-on-zeta-1-study-of-apx3330-receives-award-at-women-in-ophthalmology-wio-summer-symposium/2481795/Ocuphire Pharma announced that data from its phase 2 clinical trial of APX3330 in diabetic retinopathy (DR) were featured in an oral presentation on Saturday, August 26 at the
- Tarsus Launches Demodex Blepharitis Treatment Xdemvyhttps://modernod.com/news/tarsis-launches-demodex-blepharitis-treatment-xdemvy/2481792/Tarsus Pharmaceuticals announced that Xdemvy (lotilaner ophthalmic solution 0.25%) is now available at pharmacies nationwide for prescription. The FDA approved Xdemvy on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that w
- Bausch + Lomb Provides Update on Completion of Xiidra Acquisitionhttps://modernod.com/news/bausch-lomb-provides-update-on-completion-of-xiidra-acquisition/2481791/Bausch + Lomb announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (HSR Act) with respect to the
- Zeiss Surpasses 8 Million Eyes Treated with SMILE Worldwidehttps://modernod.com/news/zeiss-surpasses-8-million-eyes-treated-with-smile-worldwide/2481789/Zeiss announced that more than 8 million eyes have been treated with Small Incision Lenticule Extraction (SMILE) globally to date. The FDA approved the VisuMax Femtosecond Laser for the SMILE procedure in 2016. “Zeiss SMILE is a game-changer for lase